Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial
Kiyotaka Yoh, Takashi Seto, Miyako Satouchi et al. · The Lancet Respiratory Medicine · 2016
Cited by 294 works. doi:10.1016/s2213-2600(16)30322-8
Authors
- Kiyotaka Yoh
- Takashi Seto
- Miyako Satouchi
- Makoto Nishio
- Noboru Yamamoto
- Haruyasu Murakami
- Naoyuki Nogami
- Shingo Matsumoto
- Takashi Kohno
- Koji Tsuta
- Katsuya Tsuchihara
- Genichiro Ishii
- Shogo Nomura
- Akihiro Sato
- Atsushi Ohtsu
- Yuichiro Ohe
- Kōichi Goto
References
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
- Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
- Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
- First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
- Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer